Medi-Exametazim (Exametazime)

Exametazime chelates technetium‑99m to form a stable complex that, after intravenous injection, crosses the blood‑brain barrier. The complex distributes in proportion to regional cerebral blood flow, allowing SPECT cameras to detect gamma emissions and generate detailed perfusion maps of the brain.

The administered activity of Medi-Exametazim is determined by the prescribing physician or nuclear medicine specialist based on patient weight, the specific imaging protocol and regulatory guidelines. Dosage is individualized and should follow the local radiopharmacy’s preparation standards.

Safety data for exametazime in pregnancy and lactation are limited. It should only be used when the potential diagnostic benefit outweighs any possible risk to the fetus or infant. Clinicians should discuss alternatives and obtain informed consent before administration.

To place an order, submit an enquiry on the Medi-Exametazim product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Medi-Exametazim (exametazime) is a technetium‑99m based tracer, offering high image quality, a relatively short half‑life and widespread availability of Tc‑99m generators. Compared with iodine‑123 or fluorine‑18 agents, it provides lower radiation dose and can be prepared on‑site, though image resolution may be slightly lower than PET tracers.

The product must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original container. It should not be frozen or shaken, and any unused portion should be discarded according to local radiopharmaceutical waste regulations.

Medi-Exametazim is supplied as a sterile injection solution for intravenous use. It is administered by a qualified healthcare professional, typically as a single bolus injection, followed by a waiting period to allow tracer distribution before SPECT imaging commences.

Serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, pulmonary edema, and cardiac arrhythmias. Immediate medical attention is required if any of these events occur. Patients should be monitored closely during and after injection.

Medi-Exametazim is contraindicated in individuals with known hypersensitivity to exametazime, technetium‑99m or any component of the formulation. It should also be avoided in patients with unstable cardiovascular status or severe renal impairment unless the diagnostic benefit justifies use.